PAVmed Inc. (NASDAQ:PAVM) Short Interest Update

PAVmed Inc. (NASDAQ:PAVM) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 272,000 shares, a drop of 14.7% from the February 28th total of 318,700 shares. Currently, 3.8% of the shares of the company are sold short. Based on an average trading volume of 221,500 shares, the short-interest ratio is currently 1.2 days.

Institutional Trading of PAVmed

An institutional investor recently raised its position in PAVmed stock. First Manhattan CO. LLC. raised its holdings in PAVmed Inc. (NASDAQ:PAVM) by 16.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 700,000 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. First Manhattan CO. LLC. owned 6.32% of PAVmed worth $439,000 at the end of the most recent reporting period. 19.93% of the stock is currently owned by institutional investors.

PAVmed Stock Performance

NASDAQ PAVM traded down $0.01 during trading hours on Thursday, reaching $0.66. The stock had a trading volume of 15,680 shares, compared to its average volume of 107,650. PAVmed has a 52-week low of $0.57 and a 52-week high of $2.43. The stock has a market cap of $11.15 million, a P/E ratio of -0.15 and a beta of 1.13. The stock has a fifty day moving average of $0.71 and a 200 day moving average of $0.88.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets dropped their price target on PAVmed from $21.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.